Glaukos ’ iStent Has Strong Showing in 5-Year Data
This study shows that not only are Glaukosâ iStents as effective as once-daily topical travoprost in controlling IOP, but they also succeed at maintaining IOP reductions over the long-term with fewer additional medications.â
The San Clemente, CA-based company has been on full court press for a while now. Earlier this year, at the 37th annual J.P. Morgan Healthcare Conference, the company unveiled a series of products and initiatives that would see it transition into a hybrid surgical, pharmaceutical, and medical device company.
Â
Â
Source: MDDI - Category: Medical Devices Authors: Omar Ford Tags: Business Source Type: news
More News: Cataract Removal | Cataracts | Conferences | Eyes | Glaucoma | Legislation | Medical Devices | Opthalmology | Study | Travatan